Guangzhou, China– August , 2024 – Inc. “The EC approval of BAT2206 is anothersignificant accomplishment for Bio-Thera as it marks Bio-Thera’s third EC approvedproduct” said Shengfeng Li, CEO at Bio-Thera. “Bio-Thera is committed toexpanding access fo...
View DetailsBio-Thera Solutions, a global biopharmaceutical company today announced that the China National Drug Administration (CNDA) has accepted for review the Biologics License Application (BLA) for BAT1406, a proposed biosimilar to Humira(adalimumab), which...
July 25, 2018-- Bio-Thera Solutions, a clinical-stage pharmaceutical company, today announced that dosing has begun ina Phase I clinical study to compare the pharmacokinetics and safety of BAT1806, a proposed biosimilar of Actemra® (tocilizumab), to ...
In March 2018, BAT4306F, the recombinant glycosylation-modified anti-human-CD20 monoclonal antibody solution for injection, approved for phase I clinical trials in China. BAT4306Fis a next generation anti-CD20 monoclonal antibody. The CD20 receptor i...
